Search results
Results from the WOW.Com Content Network
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.
Where NICE has approved a treatment, the NHS must fund it. But not all treatments have been assessed by NICE and these treatments are usually dependent on local NHS decision making. In the case of cancer the Cancer Drugs Fund was set up in 2011 after complaints about NICE decisions on new and expensive cancer drugs with limited benefits.
The 2015 update of guidelines of the Association of Gynecological Oncology (AGO), an autonomous community of the German Society of Gynecology and Obstetrics (DGGG) and the German Cancer Society includes TARGIT IORT during lumpectomy as a recommended option for women with a T1, Grade 1 or 2, ER positive breast cancer. [5]
Cancer Treatment Centers of America (CTCA) was founded in 1988 by Richard J. Stephenson following the death of his mother, Mary Brown Stephenson, who died from lung cancer. [3] Stephenson purchased the American International Hospital in Zion, Illinois , in 1988 and expanded the hospital to include a radiation center, the Mary Brown Stephenson ...
The incidence of bronchiolo-alveolar carcinoma has been reported to vary from 4–24% of all lung cancer patients. [23] An analysis of Surveillance epidemiology and End results registry ( SEER) by Read et al. revealed that although the incidence of BAC has increased over the past two decade it still constitutes less than 4% of NSCLC in every ...
Clinical cancer centers may apply for up to $1.4 million per year. Basic Laboratory Cancer Centers conduct only laboratory research and do not provide patient treatment. Basic Laboratory Cancer Centers are more often affiliated with research institutes rather than universities. They are eligible to apply for up to $1.2 million per year. [2]
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer.The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy ...